Investment Thesis

The Cooper Companies, Inc. (COO) is a BUY at current prices due to its strong positioning in the healthcare market and its dual business model that caters to both vision care and women's health. The market is underestimating the long-term growth potential and the resilience of its competitive advantages, particularly as global demand for contact lenses and fertility services continues to expand. With the current price at $68.62, the company presents an attractive entry point, as its future revenue streams are not yet reflected in the stock price.

Competitive Moat

characterized primarily by intangible assets, including strong brand recognition and proprietary technology, particularly in the contact lens segment. The company's commitment to innovation, exemplified by advanced lenses that tackle specific vision issues, creates substantial switching costs for consumers who are likely to remain loyal to trusted brands. This advantage is durable over the next 5-10 years, although competition from lower-cost manufacturers and emerging technologies in optical care could pose threats. Major competitors like Johnson & Johnson and Alcon are continuously innovating and could erode market share if COO does not maintain its R&D momentum.

Growth Engine

Future revenue growth for COO is anticipated from both organic initiatives and strategic acquisitions. The total addressable market (TAM) for contact lenses is projected to grow significantly, driven by rising myopia rates and increasing demand for corrective lenses globally, particularly in Asia. Additionally, the CooperSurgical segment is poised for growth as awareness of women's health issues and fertility treatments rises, expanding its market share in a sector that is estimated to grow by nearly 10% annually. The company is gaining market share, especially in the myopia management space, positioning it well to capitalize on these trends.